NCT01158300 - PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG

VEGF inhibitor PTC299

This is a dose escalation study. Study participants will receive .6 or 1.2 mg/kg orally twice daily or 1.2, 1.5, or 2.0 mg/kg orally three times daily for four consecutive weeks (a course). In the absence of unacceptable toxicity or disease progression, treatment may continue for up to 12 courses (approximately one year)

Trial Locations (8)

15213

Children's Hospital of Pittsburgh, Pittsburgh

27710

Duke Comprehensive Cancer Center, Durham

38105

St. Jude Children's Research Hospital, Memphis

60614

Children's Memorial Hospital - Chicago, Chicago

94143-0128

UCSF Cancer Center and Cancer Research Institute, San Francisco

20010-2970

Children's National Medical Center, Washington D.C.

19104-4318

Children's Hospital of Philadelphia, Philadelphia

77030-2399

Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston